Does vitamin D supplementation reduce the risk of acute respiratory infections?

Why This Matters

Acute respiratory infections are extremely common and vitamin D supplements are inexpensive and widely available. Knowing which dosing patterns and which populations actually benefit helps separate a real, modest public-health-relevant effect from broader unsupported claims about vitamin D as a general immune cure-all.

What the Evidence Says

A landmark 2017 individual participant data meta-analysis pooled original data from 25 randomized controlled trials covering 11,321 participants, a more rigorous method than pooling published summary statistics alone. Vitamin D supplementation reduced the odds of experiencing at least one acute respiratory infection by about 12 percent overall. The protective effect was substantially larger in participants who were vitamin D deficient at the start of the trial, and was seen with daily or weekly dosing regimens but not with large, infrequent bolus doses. The researchers estimated that 33 people would need to receive vitamin D supplementation to prevent one case of acute respiratory infection.

• Vitamin D supplementation reduced the odds of at least one acute respiratory infection by approximately 12% overall across 25 pooled randomized trials (11,321 participants).
• The protective effect was strongest in people who were vitamin D deficient before starting supplementation.
• Daily or weekly dosing showed protective effects; large infrequent bolus doses did not show the same benefit.
• The estimated number needed to treat was 33, meaning 33 people would need supplementation to prevent one respiratory infection case.

Strength of Evidence

Moderate

This is one of the more rigorous vitamin D meta-analyses available, using individual participant data rather than pooled summary statistics, which increases confidence in the subgroup findings (deficiency status, dosing frequency). It is rated Moderate rather than Strong because the overall population-wide effect size is modest, the benefit is concentrated in specific subgroups (deficient individuals, daily/weekly dosing), and not every included trial found a significant individual effect.

What Is Still Uncertain

• The overall population-wide effect size is modest; the clearest benefit is concentrated in people who were vitamin D deficient at baseline.
• Bolus (large, infrequent) dosing regimens did not show the same protective effect as daily or weekly dosing, so dosing pattern matters and is often not specified in general vitamin D advice.
• Included trials varied in dose, baseline vitamin D status testing, and how respiratory infections were confirmed (self-report versus clinical diagnosis).
• This evidence addresses acute respiratory infections broadly; it does not establish vitamin D as a treatment for an active infection or as a substitute for vaccination.

Prevention and Risk-Reduction Context

For people with low vitamin D status, daily or weekly supplementation at guideline-appropriate doses is a reasonable, low-risk, evidence-backed part of a broader respiratory-infection risk-reduction approach. It is not a substitute for vaccination, hand hygiene, or other established prevention measures, and supplementation in people who are already vitamin D replete shows a smaller or unclear benefit.

Questions to Ask a Clinician

• Should my vitamin D level be tested before I start supplementing specifically for infection prevention?
• What daily or weekly dose is appropriate for my age, health status, and baseline vitamin D level?
• Are there risks to long-term vitamin D supplementation I should be aware of at the dose being considered?

Primary and Authoritative Sources

• Individual Participant Data Meta-Analysis
  Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data
  Martineau AR, Jolliffe DA, Hooper RL, et al. · The BMJ · 2017
  View source → · DOI: 10.1136/bmj.i6583 · PMID: 28202713
• Government Guideline
  Vitamin D: Fact Sheet for Health Professionals
  National Institutes of Health, Office of Dietary Supplements · 2024
  View source →